23andMe Holding Co. is a prominent company that values innovation, transparency, and personal empowerment. With a corporate philosophy focused on genetic research and personalized healthcare, 23andMe Holding Co. aims to revolutionize the way individuals understand their genetic information. By providing direct-to-consumer DNA testing and genetic insights, the company empowers individuals to make informed decisions about their health and well-being. With a strong commitment to privacy and ethical use of data, 23andMe Holding Co. puts the customer at the forefront, enabling them to explore their ancestry, health risks, and genetic traits. This commitment to innovation and customer-centricity highlights the core values of 23andMe Holding Co.

23andMe Holding Co. is primarily present in the United States.

23andMe Holding Co. has achieved significant milestones since its inception. The company revolutionized the genetic testing industry by introducing its direct-to-consumer DNA testing kits. By 2015, 23andMe had gathered genetic information from over one million individuals, helping to propel genetic research and contribute to breakthroughs in various scientific fields. In 2018, the company received FDA approval to offer reports on genetic health risks to its customers. This milestone allowed 23andMe to provide valuable insights into potential health conditions and empowered individuals to make informed decisions about their well-being. With its continuous innovation and commitment to genetics research, 23andMe Holding Co. remains a leading force in the field.

23andMe Holding Co. is a prominent genetic testing and biotechnology company founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. The company is based in Sunnyvale, California, and has gained significant recognition for its innovative approach to personalized medicine. 23andMe allows individuals to access and understand their genetic information, uncovering insights about their ancestry, health predispositions, and potential genetic traits. Through its saliva-based DNA testing kits, the company has enabled millions of customers to embark on a journey of self-discovery. Their services also extend to research collaborations and drug development, aiming to contribute to advancements in healthcare. 23andMe continues to be a leading player in the field of direct-to-consumer genetic testing.

The main competitors of 23andMe Holding Co. in the market include AncestryDNA, MyHeritage, and Living DNA. These companies also offer genetic testing services and provide insights into ancestry and health-related information. 23andMe Holding Co. distinguishes itself through its extensive DNA database, comprehensive reports, and strong brand recognition. However, customers may consider exploring different options and comparing the services and features offered by these competitors before making a decision on genetic testing.

23andMe Holding Co. is primarily active in the biotechnology and genetic testing industries.

The business model of 23andMe Holding Co. revolves around providing direct-to-consumer genetic testing services. As a biotechnology company, 23andMe offers personal genetic testing and analysis services to individuals interested in gaining insights into their ancestry, health conditions, and traits. By offering DNA testing kits, the company collects genetic data from customers, which is then used for research and development purposes. 23andMe primarily generates revenue through the sale of these testing kits, as well as through partnerships with pharmaceutical and biotech companies for research collaborations. Through its business model, 23andMe aims to empower individuals with genetic information and contribute to scientific advancements.

Το 23andMe Holding Co. P/E είναι -0,24.

Το KUV της εταιρείας 23andMe Holding Co. είναι 0,74.

Το AlleAktien Qualitätsscore για το 23andMe Holding Co. είναι 2/10.

Ο κύκλος εργασιών του 23andMe Holding Co. είναι 219,64 Εκ. USD.

Το 23andMe Holding Co. κέρδος είναι -666,70 Εκ. USD.

The 23andMe Holding Co. is an American company that specializes in personalized DNA tests. It was founded in 2006 by entrepreneurs Anne Wojcicki and Linda Avey and is headquartered in Mountain View, California. The business model of 23andMe is based on providing customers with insights into their health, ancestry, and genetic traits through genetic tests. The company offers a wide range of tests that allow users to determine their personal risk for certain diseases such as cancer, diabetes, and Alzheimer's. Patients can then take preventive measures to live healthier and avoid diseases. Another part of 23andMe's business model is ancestry analysis. Customers can find out where their ancestors come from and what percentage of their genetic heritage comes from different regions of the world through tests. The company also offers genetic tests to determine traits such as hair color, eye color, and height. A new focus of 23andMe is the pharmaceutical industry. The company collaborates with pharmaceutical companies to create genetic databases and support research efforts for new therapies and medications. These partnerships enable the company to raise funds for research and development of new products. 23andMe's DNA tests are sold through the company's website and can be ordered by customers worldwide. The company offers various test packages, from affordable entry-level tests to comprehensive DNA tests that provide detailed information about ancestry, various diseases, and personal traits. The products of 23andMe are based on modern DNA analysis technologies. A DNA sample is collected from customers and sent to the company. The company analyzes this sample using state-of-the-art technology and provides the results to customers in a user-friendly report. 23andMe's main source of revenue is the sale of DNA tests and partnerships with the pharmaceutical industry. Limited-edition versions of their tests have also been sold in retail stores. In summary, 23andMe operates a successful business model by offering personalized DNA tests and building partnerships with the pharmaceutical industry. With a wide range of tests that provide genetic data for health, ancestry, and personal traits, the company is well-positioned for further growth in the coming years.

Η 23andMe Holding Co. καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το 23andMe Holding Co. αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της 23andMe Holding Co. είναι US90138Q1085.

Ο τίκερ της 23andMe Holding Co. είναι ME.

Κατά τους τελευταίους 12 μήνες η 23andMe Holding Co. κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η 23andMe Holding Co. προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της 23andMe Holding Co. ανέρχεται σήμερα στο .

23andMe Holding Co. πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η 23andMe Holding Co. πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το 23andMe Holding Co. ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των 23andMe Holding Co. από την 21/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 21/9/2024.

Η τελευταία μερίσματος έγινε στις 21/9/2024.

Το έτος 2023, η 23andMe Holding Co. διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του 23andMe Holding Co. καταβάλλονται σε USD.